| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced Health Canada's approval of BRAVECTO® QUANTUM (fluralaner for extended-release injectable suspension) – a new, once-yearly injectable product.
BRAVECTO® QUANTUM is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and for the treatment and control of tick infestations with Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), and Rhipicephalus sanguineus (brown dog tick) for 12 months in dogs and puppies 6 months of age and older.
It is also indicated for the treatment and control of tick infestations with Amblyomma americanum (lone star tick) for 8 months in dogs and puppies 6 months of age and older.
BRAVECTO® QUANTUM was first approved in Australia and New Zealand in 2023, followed by the European Union in 2024, then the United States in July 2025, and now in Canada. In total, BRAVECTO® QUANTUM is currently approved in more than 50 countries worldwide.
Posted In: MRK
